Abiopharma

Revive Therapeutics Announces Extension of Proposed Private Placement

New Form 10-Q - Sigyn Therapeutics, Inc. Filed: 2025-09-05 AccNo: 0001641172-25-026704 Size: 6 MB

New Form 6-K - Theratechnologies Inc. Filed: 2025-09-05 AccNo: 0001193125-25-197146 Size: 37 KB

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

New Form 144 - UFP TECHNOLOGIES INC Filed: 2025-09-05 AccNo: 0001969223-25-000727 Size: 6 KB

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

New Form 3 - Nano-X Imaging Ltd. Filed: 2025-09-05 AccNo: 0001507133-25-000005 Size: 5 KB

Butterfly Network, Inc. - Rutgers Robert Wood Johnson Medical School Study Published in JAMA Confirms Butterfly-Enabled POCUS Program Heavily Focused on LUNG US with AI Assistance Reduces Stay and Cost

New Form 144 - COGNEX CORP Filed: 2025-09-05 AccNo: 0002054688-25-000016 Size: 5 KB

New Form 6-K - PURPLE BIOTECH LTD. Filed: 2025-09-05 AccNo: 0001213900-25-084858 Size: 578 KB

New Form 425 - Cyclacel Pharmaceuticals, Inc. Filed: 2025-09-05 AccNo: 0001641172-25-026678 Size: 45 KB

New Form 424B5 - ARTELO BIOSCIENCES, INC. Filed: 2025-09-05 AccNo: 0001640334-25-001629 Size: 557 KB

New Form 8-K - Cyclacel Pharmaceuticals, Inc. Filed: 2025-09-05 AccNo: 0001641172-25-026676 Size: 273 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits